Literature DB >> 18584311

Investigations on the humidity-induced transformations of salbutamol sulphate particles coated with L-leucine.

Janne Raula1, Frank Thielmann, Jarno Kansikas, Sami Hietala, Minna Annala, Jukka Seppälä, Anna Lähde, Esko I Kauppinen.   

Abstract

PURPOSE: The crystallization and structural integrity of micron-sized inhalable salbutamol sulphate particles coated with L-leucine by different methods are investigated at different humidities. The influence of the L-leucine coating on the crystallization of salbutamol sulphate beneath the coating layer is explored.
METHODS: The coated particles are prepared by an aerosol flow reactor method, the formation of the L-leucine coating being controlled by the saturation conditions of the L-leucine. The coating is formed by solute diffusion within a droplet and/or by vapour deposition of L-leucine. The powders are humidified at 0%, 44%, 65% and 75% of relative humidity and the changes in physical properties of the powders are investigated with dynamic vapour sorption analysis (DVS), a differential scanning calorimeter (DSC), and a scanning electron microscope (SEM).
RESULTS: Visual observation show that all the coated particles preserve their structural integrity whereas uncoated salbutamol sulphate particles are unstable at 65% of relative humidity. The coating layer formed by diffusion performs best in terms of its physical stability against moisture and moisture-induced crystallization. The degree of crystallization of salbutamol in the as-prepared powders is within the range 24-35%. The maximum degree of crystallization after drying ranges from 55 to 73% when the salbutamol crystallizes with the aid of moisture. In addition to providing protection against moisture, the L-leucine coating also stabilizes the particle structure against heat at temperatures up to 250 degrees C.
CONCLUSION: In order to preserve good flowability together with good physical stability, the best coating would contain two L-leucine layers, the inner layer being formed by diffusion (physical stability) and the outer layer by vapour deposition (flowability).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18584311     DOI: 10.1007/s11095-008-9613-4

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  24 in total

1.  Dynamics of pharmaceutical amorphous solids: the study of enthalpy relaxation by isothermal microcalorimetry.

Authors:  Jinsong Liu; Daniel R Rigsbee; Carol Stotz; Michael J Pikal
Journal:  J Pharm Sci       Date:  2002-08       Impact factor: 3.534

2.  Effect of aging on the physical properties of amorphous trehalose.

Authors:  Rahul Surana; Abira Pyne; Raj Suryanarayanan
Journal:  Pharm Res       Date:  2004-05       Impact factor: 4.200

3.  Thermodynamic quantities of surface formation of aqueous electrolyte solutions. V. Aqueous solutions of aliphatic amino acids.

Authors:  Norihiro Matubayasi; Hiroshi Miyamoto; Junji Namihira; Kentaro Yano; Tomohiro Tanaka
Journal:  J Colloid Interface Sci       Date:  2002-06-15       Impact factor: 8.128

4.  Drying-induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on Stability II: stability of a vaccine.

Authors:  Ahmad M Abdul-Fattah; Vu Truong-Le; Luisa Yee; Emilie Pan; Yi Ao; Devendra S Kalonia; Michael J Pikal
Journal:  Pharm Res       Date:  2007-02-15       Impact factor: 4.200

Review 5.  Characteristics and significance of the amorphous state in pharmaceutical systems.

Authors:  B C Hancock; G Zografi
Journal:  J Pharm Sci       Date:  1997-01       Impact factor: 3.534

6.  A study of the crystallisation of amorphous salbutamol sulphate using water vapour sorption and near infrared spectroscopy.

Authors:  Angela Columbano; Graham Buckton; Philip Wikeley
Journal:  Int J Pharm       Date:  2002-04-26       Impact factor: 5.875

7.  The effect of annealing on the stability of amorphous solids: chemical stability of freeze-dried moxalactam.

Authors:  Ahmad M Abdul-Fattah; Karen M Dellerman; Robin H Bogner; Michael J Pikal
Journal:  J Pharm Sci       Date:  2007-05       Impact factor: 3.534

8.  Inhibition of indomethacin crystallization in poly(vinylpyrrolidone) coprecipitates.

Authors:  M Yoshioka; B C Hancock; G Zografi
Journal:  J Pharm Sci       Date:  1995-08       Impact factor: 3.534

9.  Predicting the physical state of spray dried composites: salbutamol sulphate/lactose and salbutamol sulphate/polyethylene glycol co-spray dried systems.

Authors:  Deirdre O Corrigan; Owen I Corrigan; Anne Marie Healy
Journal:  Int J Pharm       Date:  2004-04-01       Impact factor: 5.875

10.  Enthalpy relaxation studies of celecoxib amorphous mixtures.

Authors:  Vasu Kumar Kakumanu; Arvind K Bansal
Journal:  Pharm Res       Date:  2002-12       Impact factor: 4.200

View more
  3 in total

1.  Nanoparticle agglomerates of fluticasone propionate in combination with albuterol sulfate as dry powder aerosols.

Authors:  Nashwa El-Gendy; Warangkana Pornputtapitak; Cory Berkland
Journal:  Eur J Pharm Sci       Date:  2011-09-21       Impact factor: 4.384

2.  Intact nanoparticulate indomethacin in fast-dissolving carrier particles by combined wet milling and aerosol flow reactor methods.

Authors:  Timo Laaksonen; Peng Liu; Antti Rahikkala; Leena Peltonen; Esko I Kauppinen; Jouni Hirvonen; Kristiina Järvinen; Janne Raula
Journal:  Pharm Res       Date:  2011-05-04       Impact factor: 4.200

3.  Structure and dissolution of L-leucine-coated salbutamol sulphate aerosol particles.

Authors:  Janne Raula; Jukka Seppälä; Jari Malm; Maarit Karppinen; Esko I Kauppinen
Journal:  AAPS PharmSciTech       Date:  2012-05-05       Impact factor: 3.246

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.